Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Torino, Italy.
University of Turin, Turin, Italy.
Bone Marrow Transplant. 2020 Oct;55(10):1918-1927. doi: 10.1038/s41409-020-0806-8. Epub 2020 Jan 29.
Patients given allogeneic hematopoietic stem cell transplantation (alloHSCT) present an increased incidence of long-term toxicities that can be attributed to the preparative regimen. We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen. In univariable analysis, we found that patients treated with TBI developed cataract in 24% of the cases compared with 4% in patients treated with BU (p = 0.0001) and that the incidence of secondary malignant neoplasia (SMN) was higher in patients treated with TBI (18%) as compared with those prepared to the allograft with a Bu-based regimen (0%) (p = 0.019). Conditioning regimen did not show a statistically significant correlation with the occurrence of all the other investigated late effects. In multivariable analysis, TBI remained associated with the occurrence of cataracts (Relative Risk: 0.33 p = 0.012) and secondary malignancies (Relative Risk 3.96 × 10e-6 p < 0.001); however, other variables, as GvHD and disease type, were also correlated with these long-term sequels, indicating that in our study population the preparative regimen is not the only factor influencing the incidence of these complications.
接受异基因造血干细胞移植(alloHSCT)的患者会出现长期毒性的发生率增加,这可归因于预处理方案。我们回顾性分析了 670 名接受 allo-HSCT 治疗急性白血病的儿童人群,根据全身照射(TBI)和白消安(BU)作为预处理方案的选择,分析了不同迟发性效应的发生情况。单变量分析发现,接受 TBI 治疗的患者中有 24%发生白内障,而接受 BU 治疗的患者中只有 4%(p=0.0001),并且接受 TBI 治疗的患者发生继发性恶性肿瘤(SMN)的发生率高于接受 BU 为基础的方案预处理的患者(0%)(p=0.019)。预处理方案与所有其他研究的迟发性效应的发生之间没有统计学上的显著相关性。多变量分析表明,TBI 仍然与白内障(相对风险:0.33,p=0.012)和继发性恶性肿瘤(相对风险 3.96×10e-6,p<0.001)的发生相关;然而,其他变量,如 GvHD 和疾病类型,也与这些长期后遗症相关,这表明在我们的研究人群中,预处理方案并不是影响这些并发症发生率的唯一因素。